HongKong Curegene Innovation

Curegene Innovation is a Hong Kong-based biotechnology company dedicated to the development of next-generation gene therapies for chronic and rare diseases. The company utilizes a proprietary AAV vector engineering platform and synthetic promoter technology to create highly efficient, tissue-specific therapeutic delivery systems. Its primary research focus spans ophthalmology, neurology, and metabolic disorders, aiming to provide long-lasting clinical benefits through single-administration treatments. Curegene's lead program, CG-001, is currently in pre-clinical development for the treatment of neovascular age-related macular degeneration. By optimizing vector design, the company seeks to overcome traditional barriers in gene therapy such as immune response and off-target effects. Headquartered in the Hong Kong Science Park, Curegene maintains strong collaborative ties with leading regional academic institutions.